Do analysts prefer TCRX or XBIO?

TScan Therapeutics presently has a consensus price target of $2.67, suggesting a potential upside of 1,020.45%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe TScan Therapeutics is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.13 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ESLA or XBIO?

Estrella Immunopharma currently has a consensus price target of $8.00, indicating a potential upside of 1,851.22%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate JSPR or XBIO?

Jasper Therapeutics currently has a consensus price target of $7.33, suggesting a potential upside of 1,186.10%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Jasper Therapeutics is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate RADX or XBIO?

Radiopharm Theranostics presently has a consensus target price of $11.00, indicating a potential upside of 873.45%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Radiopharm Theranostics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, RADX or XBIO?

Xenetic Biosciences has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 9.44 -$38.65M N/A N/A Xenetic Biosciences $2.98M 1.64 -$2.68M -$1.16 N/A

Xenetic Biosciences (XBIO) Competitors

$2.13 +0.01 (+0.47%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$2.19 +0.06 (+3.05%)

As of 10/9/2026 04:03 PM Eastern

Compare

XBIO vs. NEUP, TCRX, ESLA, JSPR, and RADX

Should you buy Xenetic Biosciences stock or one of its competitors? Xenetic Biosciences's main competitors and comparable companies include Neuphoria Therapeutics (NEUP), TScan Therapeutics (TCRX), Estrella Immunopharma (ESLA), Jasper Therapeutics (JSPR), and Radiopharm Theranostics (RADX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xenetic Biosciences compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Neuphoria Therapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Neuphoria Therapeutics' return on equity of -38.31% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Neuphoria Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 109.83%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neuphoria Therapeutics is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Xenetic Biosciences has higher revenue and earnings than Neuphoria Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17M	15.37	-$13.45M	-$6.22	N/A
Xenetic Biosciences	$2.98M	1.64	-$2.68M	-$1.16	N/A

Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market.

In the previous week, Xenetic Biosciences had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 2 mentions for Xenetic Biosciences and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.00 equaled Xenetic Biosciences'average media sentiment score.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Xenetic Biosciences	Neutral

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 1.6% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Neuphoria Therapeutics beats Xenetic Biosciences on 8 of the 14 factors compared between the two stocks.

How does Xenetic Biosciences compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TScan Therapeutics has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market.

TScan Therapeutics presently has a consensus price target of $2.67, suggesting a potential upside of 1,020.45%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe TScan Therapeutics is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Xenetic Biosciences had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for Xenetic Biosciences and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.82 beat Xenetic Biosciences' score of 1.39 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Very Positive
Xenetic Biosciences	Positive

Xenetic Biosciences has a net margin of -75.90% compared to TScan Therapeutics' net margin of -1,655.35%. Xenetic Biosciences' return on equity of -40.62% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Xenetic Biosciences has lower revenue, but higher earnings than TScan Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	1.56	-$129.77M	-$0.91	N/A
Xenetic Biosciences	$2.98M	1.64	-$2.68M	-$1.16	N/A

Summary

TScan Therapeutics and Xenetic Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Xenetic Biosciences compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Estrella Immunopharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market.

In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 2 articles in the media. Estrella Immunopharma's average media sentiment score of 0.67 beat Xenetic Biosciences' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Estrella Immunopharma	Positive
Xenetic Biosciences	Neutral

Estrella Immunopharma has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Estrella Immunopharma's return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Xenetic Biosciences has higher revenue and earnings than Estrella Immunopharma. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
Xenetic Biosciences	$2.98M	1.64	-$2.68M	-$1.16	N/A

Estrella Immunopharma currently has a consensus price target of $8.00, indicating a potential upside of 1,851.22%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Estrella Immunopharma beats Xenetic Biosciences on 8 of the 14 factors compared between the two stocks.

How does Xenetic Biosciences compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Jasper Therapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Xenetic Biosciences' return on equity of -40.62% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

79.8% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Xenetic Biosciences has higher revenue and earnings than Jasper Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Xenetic Biosciences	$2.98M	1.64	-$2.68M	-$1.16	N/A

Jasper Therapeutics has a beta of 3.16, suggesting that its stock price is 216% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market.

Jasper Therapeutics currently has a consensus price target of $7.33, suggesting a potential upside of 1,186.10%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Jasper Therapeutics is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Jasper Therapeutics had 1 more articles in the media than Xenetic Biosciences. MarketBeat recorded 3 mentions for Jasper Therapeutics and 2 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 1.39 beat Jasper Therapeutics' score of 0.54 indicating that Xenetic Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Positive
Xenetic Biosciences	Positive

Summary

Jasper Therapeutics beats Xenetic Biosciences on 8 of the 15 factors compared between the two stocks.

How does Xenetic Biosciences compare to Radiopharm Theranostics?

Radiopharm Theranostics (NASDAQ:RADX) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Xenetic Biosciences has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	9.44	-$38.65M	N/A	N/A
Xenetic Biosciences	$2.98M	1.64	-$2.68M	-$1.16	N/A

Radiopharm Theranostics has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

In the previous week, Radiopharm Theranostics had 1 more articles in the media than Xenetic Biosciences. MarketBeat recorded 3 mentions for Radiopharm Theranostics and 2 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 1.39 beat Radiopharm Theranostics' score of 0.03 indicating that Xenetic Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
Xenetic Biosciences	Positive

15.1% of Xenetic Biosciences shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Radiopharm Theranostics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Radiopharm Theranostics' return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Radiopharm Theranostics presently has a consensus target price of $11.00, indicating a potential upside of 873.45%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Radiopharm Theranostics beats Xenetic Biosciences on 8 of the 14 factors compared between the two stocks.

Get Xenetic Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIO vs. The Competition

Export

Metric	Xenetic Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.88M	$3.93B	$7.26B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-1.84	13.55	274.99	26.14
Price / Sales	1.64	1,209.42	582.85	87.95
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	0.66	17.17	11.22	6.33
Net Income	-$2.68M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-4.91%	-1.34%	-0.89%	-1.40%
1 Month Performance	-47.67%	-8.45%	-4.42%	-3.47%
1 Year Performance	-66.35%	14.02%	7.03%	1.18%

Xenetic Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIO Xenetic Biosciences	1.3826 of 5 stars	$2.13 +0.5%	N/A	-77.5%	$4.88M	$2.98M	N/A	2	Positive News Short Interest Decrease
NEUP Neuphoria Therapeutics	2.8324 of 5 stars	$3.42 -0.9%	$7.00 +104.7%	-82.4%	$18.67M	$1.17M	N/A	8
TCRX TScan Therapeutics	3.5701 of 5 stars	$0.28 +0.5%	$2.67 +863.0%	-89.0%	$18.67M	$10.32M	N/A	142	Positive News
ESLA Estrella Immunopharma	1.7319 of 5 stars	$0.42 -2.1%	$8.00 +1,804.8%	-66.7%	$18.66M	N/A	N/A	N/A	Positive News Gap Down
JSPR Jasper Therapeutics	1.6951 of 5 stars	$0.57 +1.7%	$7.33 +1,187.2%	-77.1%	$18.64M	N/A	N/A	22	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIO) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenetic Biosciences (XBIO) Competitors

XBIO vs. NEUP, TCRX, ESLA, JSPR, and RADX

How does Xenetic Biosciences compare to Neuphoria Therapeutics?

Summary

How does Xenetic Biosciences compare to TScan Therapeutics?

Summary

How does Xenetic Biosciences compare to Estrella Immunopharma?

Summary

How does Xenetic Biosciences compare to Jasper Therapeutics?

Summary

How does Xenetic Biosciences compare to Radiopharm Theranostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenetic Biosciences (XBIO) Competitors

XBIO vs. NEUP, TCRX, ESLA, JSPR, and RADX

How does Xenetic Biosciences compare to Neuphoria Therapeutics?

Is NEUP or XBIO more profitable?

Do analysts prefer NEUP or XBIO?

Which has stronger valuation and earnings, NEUP or XBIO?

Which has more volatility and risk, NEUP or XBIO?

Does the media prefer NEUP or XBIO?

Do insiders and institutionals have more ownership in NEUP or XBIO?

Summary

How does Xenetic Biosciences compare to TScan Therapeutics?

Do institutionals and insiders have more ownership in TCRX or XBIO?

Which has more volatility and risk, TCRX or XBIO?

Do analysts prefer TCRX or XBIO?

Does the media favor TCRX or XBIO?

Is TCRX or XBIO more profitable?

Which has better valuation & earnings, TCRX or XBIO?

Summary

How does Xenetic Biosciences compare to Estrella Immunopharma?

Do institutionals and insiders have more ownership in ESLA or XBIO?

Which has more risk & volatility, ESLA or XBIO?

Does the media prefer ESLA or XBIO?

Is ESLA or XBIO more profitable?

Which has preferable earnings and valuation, ESLA or XBIO?

Do analysts rate ESLA or XBIO?

Summary

How does Xenetic Biosciences compare to Jasper Therapeutics?

Is JSPR or XBIO more profitable?

Do institutionals & insiders hold more shares of JSPR or XBIO?

Which has better earnings & valuation, JSPR or XBIO?

Which has more volatility & risk, JSPR or XBIO?

Do analysts rate JSPR or XBIO?

Does the media prefer JSPR or XBIO?

Summary

How does Xenetic Biosciences compare to Radiopharm Theranostics?

Which has preferable earnings & valuation, RADX or XBIO?

Which has more volatility and risk, RADX or XBIO?

Does the media prefer RADX or XBIO?

Do insiders and institutionals believe in RADX or XBIO?

Is RADX or XBIO more profitable?

Do analysts rate RADX or XBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools